SCHEMBL3933468

SCHEMBL3933468

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCN(C)C)C(C)=O)cc1)c1ccc2cnncc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
CASP1 P29466 1/20 0.35
CSF1R P07333 3/20 0.33
AURKA O14965 1/20 0.32
RAF1 P04049 1/20 0.32
ALDH1A1 P00352 4/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 3/20 0.32
LIMK1 P53667 1/20 0.32
CHEK1 O14757 1/20 0.31
DAPK3 O43293 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31
PAK4 O96013 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933472 1.00 KMT2A (0.35) KMT2ACTDSP1CASP1CSF1RAURKA
SCHEMBL3942961 0.95 CASP1 (0.36) KMT2ACTDSP1CASP1CSF1RAURKA
SCHEMBL3942953 0.95 CASP1 (0.36) KMT2ACTDSP1CASP1CSF1RAURKA
SCHEMBL3941804 0.88 BACE1 (0.38) KMT2ACTDSP1CASP1CSF1RALDH1A1
SCHEMBL3941808 0.88 BACE1 (0.38) KMT2ACTDSP1CASP1CSF1RALDH1A1
SCHEMBL3944243 0.88 KMT2A (0.37) KMT2ACTDSP1CASP1AURKARAF1
SCHEMBL3944246 0.88 KMT2A (0.37) KMT2ACTDSP1CASP1AURKARAF1
SCHEMBL2571801 0.88 SENP1 (0.38) KMT2ACTDSP1CASP1ALDH1A1L3MBTL1
SCHEMBL30737799 0.88 SENP1 (0.38) KMT2ACTDSP1CASP1ALDH1A1L3MBTL1
SCHEMBL2571796 0.88 SENP1 (0.38) KMT2ACTDSP1CASP1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 KMT2A 1839/4885CTDSP1 673/4885CASP1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.